[go: up one dir, main page]

WO2012005898A3 - Chinese hamster ovary (cho) cell transcriptome, corresponding sirnas and uses thereof - Google Patents

Chinese hamster ovary (cho) cell transcriptome, corresponding sirnas and uses thereof Download PDF

Info

Publication number
WO2012005898A3
WO2012005898A3 PCT/US2011/040427 US2011040427W WO2012005898A3 WO 2012005898 A3 WO2012005898 A3 WO 2012005898A3 US 2011040427 W US2011040427 W US 2011040427W WO 2012005898 A3 WO2012005898 A3 WO 2012005898A3
Authority
WO
WIPO (PCT)
Prior art keywords
chinese hamster
hamster ovary
cho
cell transcriptome
corresponding sirnas
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2011/040427
Other languages
French (fr)
Other versions
WO2012005898A2 (en
Inventor
Anthony Rossomando
Stuart Pollard
John M. Maraganore
Greg Hinkle
Brian Bettencourt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alnylam Pharmaceuticals Inc
Original Assignee
Alnylam Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alnylam Pharmaceuticals Inc filed Critical Alnylam Pharmaceuticals Inc
Publication of WO2012005898A2 publication Critical patent/WO2012005898A2/en
Anticipated expiration legal-status Critical
Publication of WO2012005898A3 publication Critical patent/WO2012005898A3/en
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/50—Mutagenesis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks

Landscapes

  • Bioinformatics & Cheminformatics (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Analytical Chemistry (AREA)
  • Evolutionary Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medical Informatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The present invention provides a transcriptome of a Chinese hamster ovary cell comprising the genes expressed by the CHO cells and a set of siRNAs targeting these transcripts.
PCT/US2011/040427 2010-06-15 2011-06-15 Chinese hamster ovary (cho) cell transcriptome, corresponding sirnas and uses thereof Ceased WO2012005898A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35493210P 2010-06-15 2010-06-15
US61/354,932 2010-06-15

Publications (2)

Publication Number Publication Date
WO2012005898A2 WO2012005898A2 (en) 2012-01-12
WO2012005898A3 true WO2012005898A3 (en) 2014-04-03

Family

ID=45441711

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/040427 Ceased WO2012005898A2 (en) 2010-06-15 2011-06-15 Chinese hamster ovary (cho) cell transcriptome, corresponding sirnas and uses thereof

Country Status (1)

Country Link
WO (1) WO2012005898A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9175291B2 (en) 2012-10-11 2015-11-03 Isis Pharmaceuticals Inc. Modulation of androgen receptor expression

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2831232A4 (en) 2012-03-30 2015-11-04 Univ Washington METHODS OF MODULATING THE EXPRESSION OF TAU TO REDUCE THE STROKE AND MODIFY A NEURODEGENERATIVE SYMPTOM
WO2014062736A1 (en) 2012-10-15 2014-04-24 Isis Pharmaceuticals, Inc. Methods for monitoring c9orf72 expression
AU2013331434B2 (en) 2012-10-15 2019-08-08 Ionis Pharmaceuticals, Inc. Compositions for modulating C90RF72 expression
KR20150130430A (en) 2013-03-14 2015-11-23 아이시스 파마수티컬즈 인코포레이티드 Compositions and methods for modulating tau expression
TW202246503A (en) 2013-07-19 2022-12-01 美商百健Ｍａ公司 Compositions for modulating tau expression
KR20160062069A (en) 2013-10-11 2016-06-01 아이오니스 파마수티컬즈, 인코포레이티드 Compositions for modulating c9orf72 expression
CA2980339A1 (en) 2015-04-03 2016-10-06 University Of Massachusetts Oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders
SI3277814T1 (en) 2015-04-03 2020-12-31 University Of Massachusetts Oligonucleotide compounds for targeting huntingtin mrna
US20160319278A1 (en) 2015-04-03 2016-11-03 University Of Massachusetts Fully stabilized asymmetric sirna
AU2016249002B2 (en) 2015-04-16 2019-07-18 Ionis Pharmaceuticals, Inc. Compositions for modulating C90RF72 expression
EP3334499A4 (en) 2015-08-14 2019-04-17 University of Massachusetts BIOACTIVE CONJUGATES FOR THE ADMINISTRATION OF OLIGONUCLEOTIDES
US11260073B2 (en) 2015-11-02 2022-03-01 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating C90RF72
US10478503B2 (en) 2016-01-31 2019-11-19 University Of Massachusetts Branched oligonucleotides
EP3496758A4 (en) 2016-08-12 2020-11-11 University of Massachusetts CONJUGATED OLIGONUCLEOTIDS
JOP20190065A1 (en) 2016-09-29 2019-03-28 Ionis Pharmaceuticals Inc Compounds and Methods for Reducing the Expression of TAU
US10844377B2 (en) 2017-06-23 2020-11-24 University Of Massachusetts Two-tailed self-delivering siRNA
WO2019070704A1 (en) * 2017-10-02 2019-04-11 Georgia Tech Research Corporation Methods and compositions for engineering synthetic bioswitches for remote control of biological activity
MX2020005939A (en) 2017-12-08 2020-08-24 Synthetic Genomics Inc Improving algal lipid productivity via genetic modification of a tpr domain containing protein.
EP3775211B1 (en) * 2018-04-12 2023-04-05 MiNA Therapeutics Limited Sirt1-sarna compositions and methods of use
EP3833763A4 (en) 2018-08-10 2023-07-19 University of Massachusetts MODIFIED OLIGONUCLEOTIDES TARGETING SNPs
WO2020041769A1 (en) 2018-08-23 2020-02-27 University Of Massachusetts O-methyl rich fully stabilized oligonucleotides
BR112021009054A2 (en) 2018-11-13 2021-08-24 Lipigon Pharmaceuticals Ab Angptl4 oligonucleotides influencing the regulation of fatty acid metabolism
JP2022523467A (en) 2019-01-18 2022-04-25 ユニバーシティ・オブ・マサチューセッツ Anchors that modify dynamic pharmacokinetics
EP3976010A4 (en) * 2019-06-03 2023-08-02 Quralis Corporation OLIGONUCLEOTIDES AND METHODS OF USE IN THE TREATMENT OF NEUROLOGICAL DISEASES
BR112022002307A2 (en) 2019-08-09 2022-06-28 Univ Massachusetts CHEMICALLY MODIFIED OLIGONUCLEOTIDES TARGETING SNPS
US12365894B2 (en) 2019-09-16 2025-07-22 University Of Massachusetts Branched lipid conjugates of siRNA for specific tissue delivery
AU2022299169A1 (en) 2021-06-23 2024-02-08 Beth Israel Deaconess Medical Center, Inc. Optimized anti-flt1 oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders
WO2023076450A2 (en) * 2021-10-29 2023-05-04 Alnylam Pharmaceuticals, Inc. HUNTINGTIN (HTT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
WO2024165571A2 (en) * 2023-02-06 2024-08-15 E-Therapeutics Plc Inhibitors of expression and/or function
CN121219413A (en) * 2023-02-06 2025-12-26 e-生物有限公司 Inhibitors of expression and/or function
WO2025125576A2 (en) * 2023-12-15 2025-06-19 E-Therapeutics Plc Inhibitors of expression and/or function
CN118086310B (en) * 2024-04-19 2024-06-21 东南大学 SiRNA for inhibiting circATF IP gene expression, delivery system and application

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060275762A1 (en) * 2002-11-22 2006-12-07 Bio- Think Tank Co., Ltd., Method of detecting target base sequence of rna interference, method of designing polynucleotide base sequence causing rna interference, method of constructing double-stranded polynucleotide, method of regulating gene expression, base sequence processing apparatus, program for running base sequence processing method on comp
US20060275794A1 (en) * 2005-03-07 2006-12-07 Invitrogen Corporation Collections of matched biological reagents and methods for identifying matched reagents
US20080009012A1 (en) * 2006-03-16 2008-01-10 Dharmacon, Inc. Methods, libraries and computer program products for determining whether siRNA induced phenotypes are due to off-target effects
US20080113351A1 (en) * 2004-05-11 2008-05-15 Alphagen Co., Ltd. Polynucleotides for causing RNA interference and method for inhibiting gene expression using the same
US20090144209A1 (en) * 2004-07-07 2009-06-04 Nec Corporation Sequence prediction system

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060275762A1 (en) * 2002-11-22 2006-12-07 Bio- Think Tank Co., Ltd., Method of detecting target base sequence of rna interference, method of designing polynucleotide base sequence causing rna interference, method of constructing double-stranded polynucleotide, method of regulating gene expression, base sequence processing apparatus, program for running base sequence processing method on comp
US20080113351A1 (en) * 2004-05-11 2008-05-15 Alphagen Co., Ltd. Polynucleotides for causing RNA interference and method for inhibiting gene expression using the same
US20090144209A1 (en) * 2004-07-07 2009-06-04 Nec Corporation Sequence prediction system
US20060275794A1 (en) * 2005-03-07 2006-12-07 Invitrogen Corporation Collections of matched biological reagents and methods for identifying matched reagents
US20080009012A1 (en) * 2006-03-16 2008-01-10 Dharmacon, Inc. Methods, libraries and computer program products for determining whether siRNA induced phenotypes are due to off-target effects

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KRAMPE ET AL.: "Cell death in mammalian cell culture: molecular mechanisms and cell line engineering strategies.", CYTOTECHNOLOGY, vol. 62, no. 3, 26 May 2010 (2010-05-26), pages 175 - 88, XP019816398 *
OMASA ET AL.: "Cell engineering and cultivation of chinese hamster ovary (CHO) cells.", CURR PHARM BIOTECHNOL., vol. 11, no. 3, April 2010 (2010-04-01), pages 233 - 40, XP009143390, DOI: doi:10.2174/138920110791111960 *
WU.: "RNA interterence technology to improve recombinant protein production in Chinese hamster ovary cells.", BIOTECHNOL ADV., vol. 27, no. 4, 2009, pages 417 - 22, XP026127891, DOI: doi:10.1016/j.biotechadv.2009.03.002 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9175291B2 (en) 2012-10-11 2015-11-03 Isis Pharmaceuticals Inc. Modulation of androgen receptor expression

Also Published As

Publication number Publication date
WO2012005898A2 (en) 2012-01-12

Similar Documents

Publication Publication Date Title
WO2012005898A3 (en) Chinese hamster ovary (cho) cell transcriptome, corresponding sirnas and uses thereof
PL2589108T3 (en) Low cost, active antenna arrays
EP2568905A4 (en) Low profile electrode assembly
EP2672888A1 (en) Wireless, implantable electro-encephalography system
EP2747767B8 (en) Certain chemical entities, compositions, and methods
EP2936590B8 (en) Lmfp cathode materials with improved electrochemical performance
EP2589015A4 (en) Extracting facts from social network messages
ZA201306360B (en) Novel separator,an electrochemical cell therewith and use thereof therein
BR112014006747A2 (en) fuel cell stack and fuel cell
EP2671326A1 (en) Wireless communication with co-operating cells
WO2012031164A3 (en) Drug delivery by carbon nanotube arrays
EP2618416A4 (en) Fuel cell system
EP2671274A1 (en) Fuel cells
EP2670763A1 (en) Certain chemical entities, compositions, and methods
WO2013177248A3 (en) Modulation of enhancer rna mediated gene expression
EP3065208A4 (en) Separator-fitted single fuel cell, and fuel cell stack
EP2645460A4 (en) Fuel cell system
AU2012213753A1 (en) Trifunctional crosslinking reagents
EP2660910A4 (en) Fuel cell
WO2011117271A3 (en) Fungicidal mixtures based on azolopyrimidinylamines
EP2492999B8 (en) Fuel cell with multiple independent reaction regions
WO2012055551A3 (en) NF-ĸB SIGNAL PATH-MANIPULATED DENDRITIC CELLS
WO2013062327A3 (en) Ａｔｐｇ4 protein having productivity increase function, anti-aging function, stress resistance function of plants, genes thereof, and uses thereof
WO2012156712A3 (en) Optimising use of energy
IL238245A0 (en) Delivery of small interfering rna and micro rna through membrane-disruptive, responsive nanoscalle hydrogels

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11804024

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 11804024

Country of ref document: EP

Kind code of ref document: A2